Sopharma AD (the “Company”) announces that on 18 November 2016 the Company received a notification for the acquisition of 505 364 shares, representing 0.37% of its capital, by ZUPF Allianz Bulgaria. After the transaction the share of ZUPF Allianz Bulgaria in the capital of Sopharma AD reached 5.17%.

The date of the registration of the transaction with the Central Depository is 15 November 2016

Sopharma AD (the “Company”) announces that on 16 November 2016 the Company received a notification for the sale of 342 680 shares, representing 0.25% of its capital, by ZUPF Allianz Bulgaria. After the transaction the share of ZUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.80%.

The date of the registration of the transaction with the Central Depository is 11 November 2016.

Sopharma AD hereby notifies that following a decision of the Board of directors as of the moment Sopharma AD has acquired a total of 68% of the capital of Veta Pharma AD.

The Board of Directors of Sopharma AD decided to purchase up to 100% of the capital of “Veta Pharma” AD for a price not exceeding 2.12 BGN per share. The Board authorised the Executive Director to undertake all necessary legal actions thereby.

“Veta Pharma” AD is a modern and dynamic Bulgarian pharmaceutical porducer of 47 different products divided in three categories: medicinal products, food additives and cosmetic products. The volume of sales for 2015 exceeds 3 million packages on the Bulgarian pharmaceutical market. 50 people work at the company.

For the first ten months of this year, revenues from sales decreased by 6% compared to the same period of 2015, including 1% increase of domestic sales and 11% decrease of export sales.